Last updated on November 2019

A Phase 2 Study to Evaluate the Safety Biological Activity and PK of ND-L02-s0201 in Subjects With IPF

Brief description of study

This phase 2 clinical study will be a randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety, tolerability, biological activity, and pharmacokinetics (PK) of ND-L02-s0201 for Injection in subjects with IPF.

Clinical Study Identifier: NCT03538301

Find a site near you

Start Over

Norton Clinical Research Group

Louisville, KY United States
  Connect »